Table 1.
Phase III trials comparing cetuximab with chemotherapy in advanced NSCLC
| Trial | Treatment | n | RR (%) | PFS (months) | OS (months) | HR (95% CI) |
|---|---|---|---|---|---|---|
| FLEX19 | Ci/V | 568 | 29 | 4.8 | 10.1 | 0.87 (0.76–0.99) |
| Ci/V/Ctx | 557 | 36 | 4.8 | 11.3 | ||
| BMS 09920 | Ca/T | 338 | 17 | 4.4 | 8.4 | 0.89 (0.75–1.05) |
| Ca/T/Ctx | 338 | 26 | 4.2 | 9.7 |
Abbreviations: Ca, carboplatin; Ci, cisplatin; Ctx, cetuximab; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival; T, docetaxel/paclitaxel; V, vinoralbine; CI, confidence interval.